Johanna Lilja

Johanna Lilja

Auto-generated profile, based on publicly available information

Johanna Lilja

Turku Centre for Biotechnology, University of Turku, FI-20520 Turku, Finland

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2017 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
JLJohanna Lilja
Johanna Lilja
TZThomas Zacharchenko
Thomas Zacharchenko
MGMaria Georgiadou
Maria Georgiadou
GJGuillaume Jacquemet
Guillaume Jacquemet
NFNicola De Franceschi
Nicola De Franceschi
JIJohanna Ivaska
Johanna Ivaska
SHANK3, a synaptic scaffold protein and actin regulator, is widely expressed outside of the central nervous system with predominantly unknown function. Solving the structure of the SHANK3 N-terminal region revealed that the SPN domain is an unexpected Ras-association domain with high affinity for GTP-bound Ras and Rap G-proteins. The role of Rap1 in integrin activation is well established but the mechanisms to antagonize it remain largely unknown. Here, we show that SHANK1 and SHANK3 act as integrin activation inhibitors by sequestering active Rap1 and R-Ras via the SPN domain and thus limiting their bioavailability at the plasma membrane. Consistently, SHANK3 silencing triggers increased plasma membrane Rap1 activity, cell spreading, migration and invasion. Autism-related mutations within the SHANK3 SPN domain (R12C and L68P) disrupt G-protein interaction and fail to counteract integrin activation along the Rap1–RIAM–talin axis in cancer cells and neurons. Altogether, we establish SHANKs as critical regulators of G-protein signalling and integrin-dependent processes.

13 March 2017 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
MGMaria Georgiadou
Maria Georgiadou
JLJohanna Lilja
Johanna Lilja
GJGuillaume Jacquemet
Guillaume Jacquemet
CGCamilo Guzmán
Camilo Guzmán
MRMaria Rafaeva
Maria Rafaeva
JIJohanna Ivaska
Johanna Ivaska
Tight regulation of integrin activity is paramount for dynamic cellular functions such as cell matrix adhesion and mechanotransduction. Integrin activation is achieved through intracellular interactions at the integrin cytoplasmic tails and through integrin–ligand binding. In this study, we identify the metabolic sensor AMP-activated protein kinase (AMPK) as a β1-integrin inhibitor in fibroblasts. Loss of AMPK promotes β1-integrin activity, the formation of centrally located active β1-integrin– and tensin-rich mature fibrillar adhesions, and cell spreading. Moreover, in the absence of AMPK, cells generate more mechanical stress and increase fibronectin fibrillogenesis. Mechanistically, we show that AMPK negatively regulates the expression of the integrin-binding proteins tensin1 and tensin3. Transient expression of tensins increases β1-integrin activity, whereas tensin silencing reduces integrin activity in fibroblasts lacking AMPK. Accordingly, tensin silencing in AMPK-depleted fibroblasts impedes enhanced cell spreading, traction stress, and fibronectin fiber formation. Collectively, we show that the loss of AMPK up-regulates tensins, which bind β1-integrins, supporting their activity and promoting fibrillar adhesion formation and integrin-dependent processes.

15 June 2018 in Journal of Cell Science
Verified
Journal Article
Closed access
PDF file
JLJohanna Lilja
Johanna Lilja
JIJohanna Ivaska
Johanna Ivaska
The formation of correct synaptic structures and neuronal connections is paramount for normal brain development and a functioning adult brain. The integrin family of cell adhesion receptors and their ligands play essential roles in the control of several processes regulating neuronal connectivity – including neurite outgrowth, the formation and maintenance of synapses, and synaptic plasticity – that are affected in neurodevelopmental disorders, such as autism spectrum disorders (ASDs) and schizophrenia. Many ASD- and schizophrenia-associated genes are linked to alterations in the genetic code of integrins and associated signalling pathways. In non-neuronal cells, crosstalk between integrin-mediated adhesions and the actin cytoskeleton, and the regulation of integrin activity (affinity for extracellular ligands) are widely studied in healthy and pathological settings. In contrast, the roles of integrin-linked pathways in the central nervous system remains less well defined. In this Review, we will provide an overview of the known pathways that are regulated by integrin–ECM interaction in developing neurons and in adult brain. We will also describe recent advances in the identification of mechanisms that regulate integrin activity in neurons, and highlight the interesting emerging links between integrins and neurodevelopment.

1 February 2015 in Experimental Cell Research
Verified
Journal Article
Closed access
MWMarion Weber-Boyvat
Marion Weber-Boyvat
HKHenriikka Kentala
Henriikka Kentala
JLJohanna Lilja
Johanna Lilja
TVTerhi Vihervaara
Terhi Vihervaara
RHRaisa Hanninen
Raisa Hanninen
VOVesa Olkkonen
Vesa Olkkonen

28 May 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
MPMika Pietilä
Mika Pietilä
Pranshu SahgalPranshu Sahgal
Pranshu Sahgal
EPEmilia Peuhu
Emilia Peuhu
NJNiklas Z. Jäntti
Niklas Z. Jäntti
IPIlkka Paatero
Ilkka Paatero
JIJohanna Ivaska
Johanna Ivaska
The human epidermal growth factor receptor 2 (HER2) is an oncogene targeted by several kinase inhibitors and therapeutic antibodies. While the endosomal trafficking of many other receptor tyrosine kinases is known to regulate their oncogenic signalling, the prevailing view on HER2 is that this receptor is predominantly retained on the cell surface. Here, we find that sortilin-related receptor 1 (SORLA; SORL1) co-precipitates with HER2 in cancer cells and regulates HER2 subcellular distribution by promoting recycling of the endosomal receptor back to the plasma membrane. SORLA protein levels in cancer cell lines and bladder cancers correlates with HER2 levels. Depletion of SORLA triggers HER2 targeting to late endosomal/lysosomal compartments and impairs HER2-driven signalling and in vivo tumour growth. SORLA silencing also disrupts normal lysosome function and sensitizes anti-HER2 therapy sensitive and resistant cancer cells to lysosome-targeting cationic amphiphilic drugs. These findings reveal potentially important SORLA-dependent endosomal trafficking-linked vulnerabilities in HER2-driven cancers.

1 January 2017 in Bio-Protocol
Verified
Journal Article
Open access
PDF file
HHHellyeh Hamidi
Hellyeh Hamidi
JLJohanna Lilja
Johanna Lilja
JIJohanna Ivaska
Johanna Ivaska
Cell adhesion to neighbouring cells and to the underlying extracellular matrix (ECM) is a fundamental requirement for the existence of multicellular organisms. As such, the formation, stability and dissociation of cell adhesions are subject to tight control in space and time and perturbations within the sophisticated adhesion machinery are associated with a variety of human pathologies. Here, we outline a simple protocol to monitor alterations in cell adhesion to the ECM, for example, following genetic manipulations or overexpression of a protein of interest or in response to drug treatment, using the xCELLigence real-time cell analysis (RTCA) system. Bio-protocol is an online peer-reviewed protocol journal. Its mission is to make life science research more efficient and reproducible by curating and hosting high quality, free access protocols.